Court ruling favors GenSpera in U.S. patent dispute
By Peggy O’Hare
Mhaka had worked as a post-graduate student for two of GenSpera’s founders who obtained the patents, Johns Hopkins University professors Samuel Denmeade and John Isaacs. Mhaka claimed she should have been credited as a co-inventor of the pharmaceutical. The company denied that.
“Our defense against these claims has demonstrated GenSpera’s commitment to protecting its technologies and intellectual property portfolio,” CEO Craig Dionne said.
GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.
For more information: MySanAntonio.com/Court-ruling-favors-GenSpera-in-U-S-patent
Disclaimer/ Disclosure: The Investors News Magazine is a third party publisher of news and research as well as creates original content as a news source. Original content created by Investors News Magazine is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site may be compensated by featured companies for news submissions and content marketing. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.